Abstract
Purpose :
To investigate an additive effect of oral steroid with topical non-steroid anti-inflammatory drug (NSAID) on cystoid macula edema (CME) in patients with epiretinal membrane (ERM) after phacoemulsification and intraocular lens (IOL) implantation
Methods :
Medical records of subjects who underwent uneventful phacoemulsification and IOL implantation (n=1349) were retrospectively reviewed, and among them, changes in macular thickness and CME were compared in patients with preexisting ERM (n=81) with post-operative administration of oral steroid (n=45) for a week and without oral steroid (n=36). Topical NSAIDs were administered in both groups for 1 month. Definite or probable CME were defined by presence of changes in retinal contour with or without cystoid changes. Presence of change in central macular thickness of more than three standard deviations (SD) (≥ 90.17µm) was defined as possible CME. Macular thickness was measured 1 month after operation by optical coherence tomography.
Results :
The incidence of definite, probable and possible CME were 2.22%, 4.44%, and 8.89% with usage of steroid and 2.78%, 5.56%, 8.33% without steroid, respectively (p>0.05), and the incidences were higher compared with those in whole subjects (1.26%, 2.34% and 4.32%, n=555). Postoperative central and perifoveal macular thickness in both groups were significantly increased (p<0.05), however the differences of the macular thickness were not statistically different between those groups. Changes of macular thickness in central foveal area, perifoveal 3 mm zone and perifoveal 6 mm zone were 29.29 µm, 35.93 µm, and 38.02 µm with usage of steroid and 28.64 µm, 44.08 µm, and 45.39 µm without steroid.
Conclusions :
This study suggests that administration of oral steroid may not have a synergistic effect in reduction of CME and increased retinal thickness in patients with preexisting ERM after phacoemulsification and IOL implantation, when the topical NSAIDs are applied.
This is an abstract that was submitted for the 2016 ARVO Annual Meeting, held in Seattle, Wash., May 1-5, 2016.